Sandoz will appeal District Court of New Jersey ruling in biosimilar Erelzi® (etanercept-szzs) US patent case

  • Sandoz to appeal court ruling to United States Court of Appeals for the Federal Circuit
  • Ruling prevents launch of important, affordable treatment option for US patients affected by chronic autoimmune and inflammatory diseases
  • Sandoz remains deeply committed to providing Erelzi® as soon as possible, contributing to a more sustainable healthcare system

Holzkirchen, Germany, 9 August 2019 – Sandoz, a Novartis division and a global leader in biosimilars, today announced that the United States …

/by

Sandoz will appeal District Court of New Jersey ruling in biosimilar Erelzi® (etanercept-szzs) US patent case

  • Sandoz to appeal court ruling to United States Court of Appeals for the Federal Circuit
  • Ruling prevents launch of important, affordable treatment option for US patients affected by chronic autoimmune and inflammatory diseases
  • Sandoz remains deeply committed to providing Erelzi® as soon as possible, contributing to a more sustainable healthcare system

Holzkirchen, Germany, 9 August 2019 – Sandoz, a Novartis division and a global leader in biosimilars, today announced that the United States …

/by